GlycoOptimized GT-MAB 2.5-GEX™

glycoepitopeGT-MAB 2.5-GEX™ is a novel exceptionally potent anti-tumor specific antibody (GlycoBody) developed by GlycoDesign and GlycoOptimization, currently in clinical Phase I, Phase II starts in Q2 / 2013:

  • Main Indications: Ovarian, breast & lung cancer, further application possible in cervix, endometrium, gastrointestinal, kidney, urothelial cancers
  • Target: A new GlycoEpitope in combination with part of MUC1 (see figure)
  • Format: Humanized & glycooptimized IgG1
  • Modes of action: Very potent ADCC, apoptotic & phagocytosis mediated tumor cell killing
  • Results of GlycoOptimization:
    • Fully human glycosylation
    • Manifold improvement of anti-tumor activity
    • Optimization of bioavailability
  • Additional Highlights:
    • GlycoEpitope is very tumor specific
    • High affinity & number of binding sites
    • Very high specific accumulation in the tumor
    • Very potent anti-tumor activity in vitro and in vivo
    • Virtually no binding to human PBMCs
  • Production cell line: GlycoExpress™
  • Regulatory status: Phase I